Decline in renal function and oral anticoagulation dose reduction among patients with atrial fibrillation.

Taku InoharaDaJuanicia N HolmesKaren PieperRosalia G BlancoLarry A AllenGregg C FonarowBernard J GershElaine M HylekMichael D EzekowitzPeter R KoweyJames A ReiffelGerald V NaccarelliPaul S ChanKenneth W MahaffeyDaniel E SingerJames V FreemanBenjamin Adam SteinbergEric D PetersonJonathan P Piccininull null

Published in: Heart (British Cardiac Society) (2020)

In the US practice, about one-fourth of patients with AF had >20% decline in CrCl over time during 2 year follow-up. As a result, about 3.7% of those treated with NOACs met guideline criteria for dose reduction, but of these, only 20.1% actually had a reduction.

Keyphrases

atrial fibrillation
healthcare
primary care
venous thromboembolism
tyrosine kinase
oral anticoagulants
newly diagnosed